Among these, the estrogen receptor (ER) status stands out as a crucial biomarker, significantly influencing treatment strategies such as endocrine therapy for ER-positive breast cancers (Trayes and Cokenakes, 2021). Here, ESR1 is linked to breast carcinoma.